ClinicalTrials.gg
CompletedNCT00620867Updated Feb 21, 2021

Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)

A Phase 4 interventional study of Ibuprofen and celecoxib in Osteoarthritis, Knee, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 33 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
393
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing celecoxib in Osteoarthritis, Knee — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis, Knee.

Enrollment
3rd of 14
393 · median 216
Started
2002
with 1 other
Phase 4
10 of 14
1 open now
Registered
5th of 14
by date
Lead sponsor
6 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing celecoxib in Osteoarthritis, Knee, this one is the 3rd largest by enrollment, is one of 2 that started in 2002, is one of 10 in phase 4, and was the 5th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

1 of the 14 studies testing celecoxib in Osteoarthritis, Knee is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing celecoxib in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

To compare the efficacy and safety of celecoxib versus ibuprofen in subjects with osteoarthritis (OA) of the knee.

03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged >= 40 years old
  • Diagnosed with OA of the knee according to the American College of Rheumatology and OA in flare state at baseline visit
  • Functional capacity class of I-III

Exclusion criteria

Exclusion Criteria:

  • Inflammatory arthritis or gout or pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)
  • Acute joint trauma at index joint within the past 3 months with active symptoms
  • Score of >=20 on PHQ-9 or score of >=1 on PHQ-9 item i
  • Use of mobility assisting device for \<6 weeks or use of walker
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
393 participants (actual)

Study arms

  • Experimental
    Ibuprofen

    Drug: Ibuprofen

  • Experimental
    Celecoxib

    Drug: celecoxib

  • Placebo comparator
    placebo

    Other: placebo

Interventions

  • 800 mg oral tablet three time daily with meals for 6 weeks

  • 200 mg oral capsule once daily with morning meal for 6 weeks

  • Otherplacebo

    matched placebo orally for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in patient's assessment of arthritis pain according to visual analogue scale (VAS)

    Time frame: Week 6

Secondary outcomes

  1. Vital signs

    Time frame: Weeks 2 and 6

  2. Physical examination

    Time frame: Week 6

  3. Laboratory test results

    Time frame: Week 6

  4. Adverse events

    Time frame: Weeks 2 and 6

  5. Change from baseline in patient's and physician's global assessment of pain

    Time frame: Weeks 2 and 6

  6. Pain Satisfaction Scale

    Time frame: Days 1-7

  7. Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index

    Time frame: Week 6

  8. Patient Health Questionnaire (PHQ-9)

    Time frame: Week 6

  9. Change from baseline in patient's assessment of arthritis pain according to VAS

    Time frame: Week 2

07

Study locations

33 sites
  • Pfizer Investigational Site
    Anniston, Alabama 36207, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85051, United States
  • Pfizer Investigational Site
    Anaheim, California 92804, United States
  • Pfizer Investigational Site
    Long Beach, California 90806, United States
  • Pfizer Investigational Site
    Paramount, California 90723, United States
  • Pfizer Investigational Site
    San Diego, California 92108, United States
  • Pfizer Investigational Site
    DeLand, Florida 32720, United States
  • Pfizer Investigational Site
    Miami, Florida 33186, United States
  • Pfizer Investigational Site
    Naples, Florida 34102, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida 33024, United States
  • Pfizer Investigational Site
    Saint Petersburg, Florida 33710, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60610, United States
  • Pfizer Investigational Site
    Evansville, Indiana 47712, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89102, United States
  • Pfizer Investigational Site
    Edison, New Jersey 08817, United States
  • Pfizer Investigational Site
    South Plainfield, New Jersey 07080, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87109, United States
  • Pfizer Investigational Site
    Brooklyn, New York 11203, United States
  • Pfizer Investigational Site
    New York, New York 10022-1009, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45242, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43124, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma 74136, United States
  • Pfizer Investigational Site
    Altoona, Pennsylvania 16601, United States
  • Pfizer Investigational Site
    Jenkintown, Pennsylvania 19046, United States
  • Pfizer Investigational Site
    Newtown, Pennsylvania 18940, United States
  • Pfizer Investigational Site
    Warwick, Rhode Island 02886, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29407, United States
  • Pfizer Investigational Site
    Greer, South Carolina 29651, United States
  • Pfizer Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • Pfizer Investigational Site
    Johnson City, Tennessee 37601, United States
  • Pfizer Investigational Site
    Dallas, Texas 75235, United States
  • Pfizer Investigational Site
    Layton, Utah 84041, United States
  • Pfizer Investigational Site
    Danville, Virginia 24541, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002, a primary completion of Mar 2003 and a completion of Mar 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2008
First posted
Feb 22, 2008
Start
Oct 2002
Primary completionActual
Mar 2003
CompletionActual
Mar 2003
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00620867
Responsible party
Sponsor
First posted
Feb 22, 2008
Start date
Oct 2002
Primary completion
Mar 2003
Completion
Mar 2003
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Celecoxib

Start the discussion